Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on November 15, 2012. The report discloses significant changes in the Company's executive leadership, specifically regarding the Chief Financial Officer position.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: R. Don Elsey, the Company's Chief Financial Officer, resigned effective December 3, 2012.
- Appointment: Robert G. Kramer, currently the Executive Vice President of the Corporate Services Division, was appointed to the roles of Chief Financial Officer, Principal Financial and Accounting Officer, and Treasurer, effective December 3, 2012.
Management Commentary and Background
Mr. Kramer, 55, has served as Executive Vice President of the Corporate Services Division since September 2012. Prior to this, he served as a consultant to the Company from September 2011 through August 2012. His extensive history with the organization includes serving as President and CEO of Emergent BioDefense Operations Lansing Inc. (formerly BioPort Corporation) from 2004 to 2009. Before joining BioPort in 1999, Mr. Kramer held financial management positions at Pharmacia Corp. and Northwest Industries.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (December 3, 2012).
- Review the attached Press Release (Exhibit 99.1) for additional details on the leadership change.
- Monitor upcoming quarterly filings for any impact on financial reporting consistency due to the leadership change.